USO 23335

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA (R3767-ONC-22122)

Disease Types: Melanoma Research

Eligibility Requirements:

• Histologically confirmed unresectable stage III and stage IV
(metastatic) melanoma
• Uveal, acral or mucosal melanoma are not eligible
• No prior systemic therapy for unresectable or metastatic
melanoma
• Pt with adjuvant/neoadjuvant therapy without PD during treatment
are eligible if disease-free and treatment-free for over 6 months
• No prior immune checkpoint inhibitor therapy other than anti-PD1/PD-L1
• Measurable disease per RECIST version 1.1
• Previously irradiated lesions can be used as target lesions only if
demonstrated to progress and no other target lesion is available
• Cutaneous lesions are considered non-target lesions
• Patients must have known BRAF V600 status

For more information on this trial CLICK HERE .

Available at:

• Norfolk (Brock Cancer Center)
• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Virginia Beach (Princess Anne)
• Williamsburg